Targeting Regulated Cell Death (RCD) with Small-molecule Compounds in Triple-negative Breast Cancer: a Revisited Perspective from Molecular Mechanisms to Targeted Therapies

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2022 Apr 13

PMID 35414025

Authors

Minru Liao

Rui Qin

Wei Huang

Hong-Ping Zhu

Fu Peng

Bo Han

Bo Liu

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is a subtype of human breast cancer with one of the worst prognoses, with no targeted therapeutic strategies currently available. Regulated cell death (RCD), also known as programmed cell death (PCD), has been widely reported to have numerous links to the progression and therapy of many types of human cancer. Of note, RCD can be divided into numerous different subroutines, including autophagy-dependent cell death, apoptosis, mitotic catastrophe, necroptosis, ferroptosis, pyroptosis and anoikis. More recently, targeting the subroutines of RCD with small-molecule compounds has been emerging as a promising therapeutic strategy, which has rapidly progressed in the treatment of TNBC. Therefore, in this review, we focus on summarizing the molecular mechanisms of the above-mentioned seven major RCD subroutines related to TNBC and the latest progress of small-molecule compounds targeting different RCD subroutines. Moreover, we further discuss the combined strategies of one drug (e.g., narciclasine) or more drugs (e.g., torin-1 combined with chloroquine) to achieve the therapeutic potential on TNBC by regulating RCD subroutines. More importantly, we demonstrate several small-molecule compounds (e.g., ONC201 and NCT03733119) by targeting the subroutines of RCD in TNBC clinical trials. Taken together, these findings will provide a clue on illuminating more actionable low-hanging-fruit druggable targets and candidate small-molecule drugs for potential RCD-related TNBC therapies.

Citing Articles

GluOC Induced SLC7A11 and SLC38A1 to Activate Redox Processes and Resist Ferroptosis in TNBC.

Xu J, Bai X, Dong K, Du Q, Ma P, Zhang Z Cancers (Basel). 2025; 17(5).

PMID: 40075587 PMC: 11899354. DOI: 10.3390/cancers17050739.

A first-in-class selective inhibitor of ERK1/2 and ERK5 overcomes drug resistance with a single-molecule strategy.

Xiao H, Wang A, Shuai W, Qian Y, Wu C, Wang X Signal Transduct Target Ther. 2025; 10(1):70.

PMID: 39979271 PMC: 11842588. DOI: 10.1038/s41392-025-02169-z.

Comprehensive exploration of programmed cell death landscape in lung adenocarcinoma combining multi-omic analysis and experimental verification.

Yu P, Xiao L, Hu K, Ling J, Chen Y, Liang R Sci Rep. 2025; 15(1):5364.

PMID: 39948103 PMC: 11825851. DOI: 10.1038/s41598-025-87982-w.

Multi‑omics identification of a novel signature for serous ovarian carcinoma in the context of 3P medicine and based on twelve programmed cell death patterns: a multi-cohort machine learning study.

Ye L, Long C, Xu B, Yao X, Yu J, Luo Y Mol Med. 2025; 31(1):5.

PMID: 39773329 PMC: 11707953. DOI: 10.1186/s10020-024-01036-x.

Pirfenidone promotes cell cycle arrest and apoptosis of triple‑negative breast cancer cells by suppressing Hedgehog/GLI1 signaling.

Shi S, Zhao L, Liu C, Xiao H, Jiang Z Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39621085 DOI: 10.1007/s00210-024-03652-0.

References

Hurley J, Young L . Mechanisms of Autophagy Initiation. Annu Rev Biochem. 2017; 86:225-244. PMC: 5604869. DOI: 10.1146/annurev-biochem-061516-044820. View

Li Y, Xiao Y, Lin H, Reichel D, Bae Y, Lee E . In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis. Biomaterials. 2018; 188:160-172. DOI: 10.1016/j.biomaterials.2018.10.019. View

Santucci R, Sinibaldi F, Cozza P, Polticelli F, Fiorucci L . Cytochrome c: An extreme multifunctional protein with a key role in cell fate. Int J Biol Macromol. 2019; 136:1237-1246. DOI: 10.1016/j.ijbiomac.2019.06.180. View

Kiraz Y, Adan A, Yandim M, Baran Y . Major apoptotic mechanisms and genes involved in apoptosis. Tumour Biol. 2016; 37(7):8471-86. DOI: 10.1007/s13277-016-5035-9. View

Lu Y, Zhao X, Liu Q, Li C, Graves-Deal R, Cao Z . lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. Nat Med. 2017; 23(11):1331-1341. PMC: 5961502. DOI: 10.1038/nm.4424. View

Chen X, Li J, Gray W, Lehmann B, Bauer J, Shyr Y . TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Inform. 2012; 11:147-56. PMC: 3412597. DOI: 10.4137/CIN.S9983. View

Song X, Wang X, Liu Z, Yu Z . Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib. Front Oncol. 2021; 10:597434. PMC: 7785974. DOI: 10.3389/fonc.2020.597434. View

Yan H, Luo B, Wu X, Guan F, Yu X, Zhao L . Cisplatin Induces Pyroptosis via Activation of MEG3/NLRP3/caspase-1/GSDMD Pathway in Triple-Negative Breast Cancer. Int J Biol Sci. 2021; 17(10):2606-2621. PMC: 8315016. DOI: 10.7150/ijbs.60292. View

Kim S, Min A, Lee K, Yang Y, Kim T, Lim J . Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis. Cancer Res Treat. 2016; 49(3):643-655. PMC: 5512373. DOI: 10.4143/crt.2016.168. View

10.

Chiu H, Yeh Y, Ho S, Wu Y, Wang B, Huang W . A New Histone Deacetylase Inhibitor Enhances Radiation Sensitivity through the Induction of Misfolded Protein Aggregation and Autophagy in Triple-Negative Breast Cancer. Cancers (Basel). 2019; 11(11). PMC: 6896096. DOI: 10.3390/cancers11111703. View

11.

Liu Y, Wang L, Liu J, Xie X, Hu H, Luo F . Anticancer Effects of ACT001 via NF-κB Suppression in Murine Triple-Negative Breast Cancer Cell Line 4T1. Cancer Manag Res. 2020; 12:5131-5139. PMC: 7326172. DOI: 10.2147/CMAR.S244748. View

12.

Dyari H, Rawling T, Chen Y, Sudarmana W, Bourget K, Dwyer J . A novel synthetic analogue of ω-3 17,18-epoxyeicosatetraenoic acid activates TNF receptor-1/ASK1/JNK signaling to promote apoptosis in human breast cancer cells. FASEB J. 2017; 31(12):5246-5257. DOI: 10.1096/fj.201700033R. View

13.

Li Z, Hou Y, Hao G, Pan X, Fei H, Wang F . CUDC-907 enhances TRAIL-induced apoptosis through upregulation of DR5 in breast cancer cells. J Cell Commun Signal. 2020; 14(4):377-387. PMC: 7642015. DOI: 10.1007/s12079-020-00558-3. View

14.

Synnott N, Bauer M, Madden S, Murray A, Klinger R, ODonovan N . Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. Cancer Lett. 2017; 414:99-106. DOI: 10.1016/j.canlet.2017.09.053. View

15.

Tian S, Chen Y, Yang B, Lou C, Zhu R, Zhao Y . F1012-2 inhibits the growth of triple negative breast cancer through induction of cell cycle arrest, apoptosis, and autophagy. Phytother Res. 2018; 32(5):908-922. DOI: 10.1002/ptr.6030. View

16.

Liang Z, Wan Y, Zhu D, Wang M, Jiang H, Huang D . Resveratrol Mediates the Apoptosis of Triple Negative Breast Cancer Cells by Reducing POLD1 Expression. Front Oncol. 2021; 11:569295. PMC: 7970754. DOI: 10.3389/fonc.2021.569295. View

17.

Turco E, Fracchiolla D, Martens S . Recruitment and Activation of the ULK1/Atg1 Kinase Complex in Selective Autophagy. J Mol Biol. 2019; 432(1):123-134. PMC: 6971721. DOI: 10.1016/j.jmb.2019.07.027. View

18.

Timmerman L, Holton T, Yuneva M, Louie R, Padro M, Daemen A . Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013; 24(4):450-65. PMC: 3931310. DOI: 10.1016/j.ccr.2013.08.020. View

19.

Knight T, Luedtke D, Edwards H, Taub J, Ge Y . A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. Biochem Pharmacol. 2019; 162:250-261. DOI: 10.1016/j.bcp.2019.01.015. View

20.

Yuan X, Gajan A, Chu Q, Xiong H, Wu K, Wu G . Developing TRAIL/TRAIL death receptor-based cancer therapies. Cancer Metastasis Rev. 2018; 37(4):733-748. PMC: 6138568. DOI: 10.1007/s10555-018-9728-y. View